Hot Investor Mandate 1: Korean VC Firm with Pharma Affiliation Seeks to Invest in Early Stage Therapeutics Assets, Most Interested in Oncology and Autoimmune Disease

5 Jul

A Seoul-based venture capital firm founded in 2015 and affiliated with a leading pharmaceutical company in South Korea closed their first fund in 2016 and has recently raised a second fund of approximately $60M USD. The firm has made 8 investments to date, in 3 Korean and 5 USA-based companies. The firm continues to seek global opportunities. The firm generally participates in financings of Series B and beyond, participating in Series A rounds on a case-by-case basis. However, the firm has started to look for earlier stage opportunities and is most interested in spin-out assets and forming new companies in South Korea. Within this angle, the firm is highly interested in companies who are interested in entering the Korean market and looking to leverage on the capital and clinical infrastructure in South Korea.

The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.

With regards to companies raising a Series A round, the firm prefers working with experienced management teams with high-profile scientific founders being involved. The firm incorporates a different strategy depending on the company’s headquarters. For companies based in South Korea, the firm serves as a hands-on, active investor and seeks board representation. In the USA, the firm prefers to be a more passive investor and generally seeks to co-invest with established venture capital firms that have a footprint in the USA.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: